Case Number:

IPR2021-00406

Case Type:

IPR

Status:

Final Written Decision

Petitioner:

Liquidia Technologies, Inc.

Patent Owner:

United Therapeutics Corporation

Patent Number:

10716793

Tech Center:

1600

1. Filed: January 07, 2021 00:00

   Coverage

   1. July 20, 2022

      PTAB Axes Hypertension Drug IP Involved In Generic Fight

      The Patent Trial and Appeal Board has invalidated a United Therapeutics Corp. patent on Tyvaso, its inhalable treatment for pulmonary hypertension, giving a boost to efforts by challenger Liquidia Technologies Inc. to obtain federal approval for a generic version of the drug.

   ---

   Stay ahead of the curve

   In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

   
   

   • Search PTAB cases and full-text documents.
   • Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
   • Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!

   TRY LAW360 FREE FOR SEVEN DAYS

   View the PTAB case documents

   Already a subscriber? Click here to login